Want to see MAIA full AI Analyst Report?
Top Page
MAIA Biotechnology, Inc.
(MAIA)
Select Model
Select Model
Rating:44Neutral
Price Target:―
Action:N/A
Date:05/03/25
MAIA Biotechnology presents a mixed outlook. The company's financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
Positive Factors
Clinical Trial Success
The promising results from the Phase 2 THIO-101 trial indicate a potential breakthrough in cancer treatment, enhancing MAIA's regulatory strategy and expediting FDA approval, which could significantly boost the company's market position and revenue potential.
Negative Factors
Lack of Revenue
The absence of revenue generation reflects the company's early-stage status and reliance on external funding, posing a risk to financial sustainability and limiting its ability to self-fund R&D and operational activities in the long term.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Trial Success
The promising results from the Phase 2 THIO-101 trial indicate a potential breakthrough in cancer treatment, enhancing MAIA's regulatory strategy and expediting FDA approval, which could significantly boost the company's market position and revenue potential.
Read all positive factors
MAIA Biotechnology, Inc. (MAIA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$86.34M
Dividend YieldN/A
Average Volume (3M)570.23K
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue GrowthN/A
EPS Growth16.55%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.63
Shares Outstanding60,800,760
10 Day Avg. Volume650,834
30 Day Avg. Volume570,232
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)20.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.61
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.68
Forecast
1Y Price Target
$14.00Price Target Upside993.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
MAIA Biotechnology, Inc. Business Overview & Revenue Model
Company Description
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, TH...
How the Company Makes Money
MAIA Biotechnology, Inc. makes money primarily through the development and commercialization of oncology therapies. The company's revenue model includes securing funding through partnerships, licensing agreements, and collaborations with other pha...
MAIA Biotechnology, Inc. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -17.11M | -22.40M | -23.25M | -19.77M | -15.76M | -11.75M |
| Net Income | -26.85M | -22.40M | -23.25M | -19.77M | -15.77M | -12.50M |
Balance Sheet | ||||||
| Total Assets | 28.24M | 9.70M | 10.16M | 7.57M | 12.02M | 11.33M |
| Cash, Cash Equivalents and Short-Term Investments | 27.60M | 8.66B | 9.60M | 7.15M | 10.95M | 10.57M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 7.57M | 7.33M | 6.52M | 7.09M | 3.51M | 2.15M |
| Stockholders Equity | 20.68M | 2.38M | 3.63M | 477.51K | 8.51M | 9.18M |
Cash Flow | ||||||
| Free Cash Flow | -22.57M | -18.84M | -15.70M | -13.07M | -12.10M | -4.12M |
| Operating Cash Flow | -22.57M | -18.84M | -15.70M | -13.07M | -12.10M | -4.12M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 40.02M | 17.91M | 18.18M | 9.27M | 12.48M | 14.03M |
MAIA Biotechnology, Inc. Technical Analysis
Positive
1.28
Price Trends
1.36
Positive
1.35
Positive
1.46
Negative
Market Momentum
<0.01
Negative
57.36
Neutral
80.95
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MAIA, the sentiment is Positive. The current price of 1.28 is below the 20-day moving average (MA) of 1.33, below the 50-day MA of 1.36, and below the 200-day MA of 1.46, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.36 is Neutral, neither overbought nor oversold. The STOCH value of 80.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MAIA.
MAIA Biotechnology, Inc. Risk Analysis
MAIA Biotechnology, Inc. disclosed 89 risk factors in its most recent earnings report. MAIA Biotechnology, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MAIA Biotechnology, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $167.65M | -1.16 | -49.02% | ― | ― | 34.92% | |
46 Neutral | $37.40M | -4.61 | -45.89% | ― | -100.00% | 63.20% | |
44 Neutral | $86.34M | -2.22 | -284.80% | ― | ― | 16.55% | |
43 Neutral | $36.74M | -0.85 | -93.08% | ― | 110.08% | 76.04% | |
42 Neutral | $60.29M | -1.67 | -117.24% | ― | 476.71% | 70.23% |
* Healthcare Sector Average
MAIA
MAIA Biotechnology, Inc.
1.41
-0.16
-10.19%
VERU
Veru
2.77
-0.40
-12.62%
OKUR
OnKure Therapeutics
4.06
2.06
103.00%
XLO
Xilio Therapeutics
9.20
-0.60
-6.12%
RADX
Radiopharm Theranostics Limited Sponsored ADR
2.80
-2.42
-46.36%
MAIA Biotechnology, Inc. Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
MAIA Biotechnology Showcases THIO-101 Trial at ELCC 2025
Positive
Mar 28, 2025
MAIA Biotechnology, Inc. presented a poster at the European Lung Cancer Congress 2025 on March 28, 2025, showcasing efficacy data from its Phase 2 THIO-101 clinical trial. The trial evaluates THIO in combination with the immune checkpoint inhibito...
Executive/Board ChangesBusiness Operations and Strategy
MAIA Biotechnology Updates Executive Compensation Packages
Neutral
Feb 6, 2025
On February 1, 2025, MAIA Biotechnology, Inc. announced updates to the employment agreements of key executives, including Dr. Vlad Vitoc, Chairman and CEO, and Dr. Sergei Gryaznov, Chief Scientific Officer. These amendments included salary increas...
Product-Related AnnouncementsBusiness Operations and Strategy
MAIA Biotechnology Reports Promising Phase 2 Trial Results
Positive
Feb 5, 2025
On February 4, 2025, MAIA Biotechnology announced positive updates from its Phase 2 THIO-101 trial for advanced non-small cell lung cancer. The trial showed a significant median overall survival of 16.9 months, suggesting a strong advantage over s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.